JCR Pharmaceuticals Co., Ltd.

• Osiris Therapeutics and JCR Pharmaceuticals Co., Ltd. Announce Mesenchymal Stem Cell Alliance for Japan; Alliance to Develop and Commercialize Treatment for Hematologic Malignancies.

Business Editors/Health/Medical Writers BIOWIRE2K BALTIMORE & ASHIYA, Japan--(BUSINESS WIRE)--Aug. 27, 2003 Osiris Therapeutics, Inc. and JCR Ph...

• Business Wire
• August 27, 2003

• BIO-TECHNOLOGY GENERAL ANNOUNCES LICENSE OF OXSODROL(TM), HUMAN SOD, TO JCR PHARMACEUTICALS CO., LTD. OF JAPAN.

ISELIN, N.J.--(BUSINESS WIRE)--January 10, 1995--Bio-Technology General Corp. (NASDAQ:BTGC) today announced that JCR Pharmaceuticals Co., Ltd. has obt...

• Business Wire
• January 10, 1995

• Maven Semantic: Inflammatory Bowel Research Database.

... -- Maven Semantic (http://www.mavensemantic.com) announces updates to their Inflammatory Bowel res...* Alimentary Health Ltd. * ALTUS PHARMACEUTICALS, INC. * AmeriPath, Inc. *...

• Business Wire
• July 05, 2011

• Insuring Understanding: The Tested Language Defense

Introduction. A. Contra Proferentem. B. Reasonable Expectations. C. Facing Complexity. II. Consumer Misperception. A. Mistakes. B. Some implications. C. Why Mistakes Persist: Misperception and Missing Perception. D. Insurers as Poor Educators. III. Rewarding Plain Language. A. Testing the Language. B. The defense applied to Contra Proferentem. C. The Defense Applied to Reasonable Expectations. D. Ambiguity and Complexity. IV. Enjoying Plain Language. A. Benefitting from Plain Language. B. Some Objections to the Defense. 1. Necessity. 2. Giving an “A” for Effort. 3. Structural Ambiguity. 4. Overt Judicial Regulation. V. Conclusion. Appendix: Other Educational Sources.

... 1164–68 (2005) (same, regarding pharmaceuticals); Tülin Erdem, Michael P. Keene, T. Sabri Öncü ..., 11 (Da Capo Press & Theatrum Orbis Terrarum Ltd., photo. reprint 1969) (1630). The doctrine “is ...

• Iowa Law Review
• Nbr. 95-4, May 2010

• Maven Semantic: Database of International Inflammatory Bowel Disease Research.

... -- Maven Semantic (http://www.mavensemantic.com) announces updates to their Inflammatory Bowel Dis...* Corixa Corporation. * Oxagen Ltd. * Astra Draco AB. * Genentech, Inc. * Immunex Cor...* Inotek Pharmaceuticals Corporation. * JCR Pharmaceuticals Co., Ltd. * Mil...

• Business Wire
• August 25, 2010

• CRUCELL REPORTS FIRST QTR 2005 REVENUE UP 50% OVER 2004.

Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL), has announc...-DSM alliance with Roche, JCR Pharmaceuticals and Mitsubishi. Crucell signed further PER.C6 dealls with SingVax and Vascular Biogenics Ltd. . * Intellectual property: Crucell received a Eur...

• Biotech Financial Reports
• Vol. 12 Nbr. 6, June 2005

• TPG Biotech to Fund Development of JCR Pharmaceuticals Drug Candidates.

TOKYO -- TPG Biotech and JCR Pharmaceuticals Co., Ltd. of Ashiya, Japan jointly announced that the...

• Business Wire
• March 12, 2008

• Osiris and JCR Pharmaceuticals Reach Milestone, Expand License Agreement; Companies to Expand Stem Cell Technology into a New Market Opportunity.

...Ltd. of Ashiya, Japan, allowing JCR to sell stem cells...

• Business Wire
• August 04, 2005

• CepTor Corporation Announces Exclusive License Agreement for Myodur in the Pacific Rim with JCR Pharmaceuticals.

...-year license to JCR Pharmaceuticals Co., LTD. of Japan to develop and commercialize its lead pr...

• Business Wire
• March 02, 2005

• Reportlinker Adds World Syringes (Reusable and Disposable) Market Report.

NEW YORK -- Reportlinker.com announces that a new market research report is ava... Syringes, Inc., Smiths Medical International Ltd., Terumo Corporation, and Terumo Medical Corporati... Systems, Inc (USA) -Merlyn Pharmaceuticals, Inc (USA) -MGlas AG (Germany) -Misawa Medical Ind...

• Business Wire
• March 24, 2009